<SEC-DOCUMENT>0001193125-12-317944.txt : 20120727
<SEC-HEADER>0001193125-12-317944.hdr.sgml : 20120727
<ACCEPTANCE-DATETIME>20120727060824
ACCESSION NUMBER:		0001193125-12-317944
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20120726
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120727
DATE AS OF CHANGE:		20120727

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-176897
		FILM NUMBER:		12988704

	BUSINESS ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d386563d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="4"><B>UNITED STATES SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WASHINGTON, D.C. 20549
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Pursuant to Section&nbsp;13 or 15(d) of the Securities
Exchange Act of 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Date of Report (Date of Earliest Event Reported): July&nbsp;26, 2012 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Amarin Corporation plc </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Exact name of registrant as specified in its charter) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>England and Wales</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0-21392</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not applicable</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction of <BR>incorporation)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer<BR>Identification No.)</B></FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2 Pembroke House, Upper Pembroke</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Street 28-32,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Dublin 2, Ireland</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not applicable</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Registrant&#146;s telephone number,
including area code: +353 1 6699 020 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not Applicable </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Former name or former address, if changed since last report </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Events </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On July&nbsp;26, 2012, Amarin Corporation plc issued a press release titled, &#147;Amarin Announces FDA Approval of Vascepa</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (icosapent ethyl) Capsules for the Reduction of Triglyceride Levels in Adult Patients with Severe
(TG<U>&gt;</U>500mg/dL) Hypertriglyceridemia.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A copy of the press release is attached hereto as Exhibit&nbsp;99.1 and
is incorporated herein by reference. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d)&nbsp;Exhibits. </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release dated July&nbsp;26, 2012.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">AMARIN CORPORATION PLC</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ John Thero</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">John Thero</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">President</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: July&nbsp;27, 2012 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT&nbsp;INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release dated July&nbsp;26, 2012.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d386563dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g386563g60u40.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Amarin Announces FDA Approval of Vascepa<FONT STYLE="font-family:Times New Roman" SIZE="2"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> (icosapent ethyl) Capsules for the </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Reduction of Triglyceride Levels in Adult Patients with Severe (TG </B><U>&gt;</U><B>500 mg/dL) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Hypertriglyceridemia </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g386563g05u28.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>-Approval Based on Positive Results from MARINE Study- </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>-Conference Call Scheduled for Today, July&nbsp;26th at 7:00 p.m. EDT- </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">BEDMINSTER, N.J., and DUBLIN, Ireland, July&nbsp;26, 2012 &#151; Amarin Corporation plc&nbsp;(Nasdaq: AMRN), a biopharmaceutical
company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the U.S. Food and Drug Administration (FDA) has approved Vascepa<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> (icosapent ethyl) capsules (formerly known as AMR101) as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (TG <U>&gt;</U>500mg/dL)
hypertriglyceridemia (very high triglycerides). Amarin submitted the New Drug Application (NDA) for the use of Vascepa in this indication in September 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;FDA approval of Vascepa represents the introduction of an important new treatment option for patients with severe hypertriglyceridemia. In Amarin&#146;s MARINE clinical trial, Vascepa demonstrated a
statistically significant placebo-adjusted reduction in levels of triglycerides without elevation in levels of LDL-C, commonly referred to as &#145;bad cholesterol,&#146;&#148; stated Joseph Zakrzewski, Chairman and CEO of Amarin. &#147;Amarin
continues to anticipate commercial launch of Vascepa early in the first quarter of 2013, and we continue to consider three potential paths for the marketing and sale of the product: an acquisition of Amarin, a strategic collaboration, or
self-commercialization, the latter of which could include third-party support. We are now focused on continued commercial preparations for Vascepa which includes, but is not limited to, finalizing the introduction of Vascepa to managed care plans to
gain formulary access, building-up inventory levels and coordinating other pre-launch marketing activities.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The efficacy and safety of
Vascepa were assessed in Amarin&#146;s MARINE clinical trial, a randomized, placebo-controlled, double-blind, parallel-group study of adult patients with very high fasting triglyceride levels, between 500 mg/dL and 2000 mg/dL. At baseline, 25% of
patients were on concomitant statin therapy, 28% were diabetics, and 39% of patients had TG levels greater than 750 mg/dL. Patients treated for 12 weeks with the 4 gram dose of Vascepa demonstrated a statistically significant placebo-adjusted median
triglyceride reduction of 33% (p&lt;0.001), and did not show an increase in LDL-C levels relative to placebo. Vascepa 4 grams per day also showed statistically significant placebo-adjusted median reductions from baseline in non-HDL-C (total
cholesterol less &#147;good cholesterol&#148;) of 18%, Total Cholesterol (TC) of 16%, </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Very Low Density Lipoprotein Cholesterol (VLDL-C) of 29%, and apolipoprotein B (Apo B) of 9%. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The most commonly reported adverse reaction (incidence &gt;2% and greater than placebo) in Vascepa treated patients was arthralgia (joint pain) (2.3% for Vascepa vs. 1.0% for placebo). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows the changes in major lipoprotein and lipid parameters for the treatment groups: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Median Baseline and Percent Change from Baseline in Lipid Parameters in Patients with </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Severe (</B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B></B><B>500 mg/dL) Hypertriglyceridemia </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:36pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Parameter</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Vascepa 4 g/day<BR>N=76</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Placebo<BR>N=75</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Difference (95%<BR>Confidence<BR>Interval)</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Baseline</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>%<BR>Change</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Baseline</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>%<BR>Change</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">TG (mg/dL)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">680</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">-27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">703</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">+10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-33*&nbsp;(-47,&nbsp;-22)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">LDL-C (mg/dL)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">91</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">-5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">86</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">-3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-2 (-13, +8)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-HDL-C (mg/dL)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">-8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">229</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">+8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-18 (-25, -11)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">TC (mg/dL)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">254</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">-7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">256</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">+8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-16 (-22, -11)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">HDL-C (mg/dL)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">-4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-4 (-9, +2)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">VLDL-C (mg/dL)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">123</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">-20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">124</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">+14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-29**&nbsp;(-43,&nbsp;-14)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Apo B (mg/dL)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">121</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">-4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">+4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-9**(-14, -3)</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1">% Change= Median Percent Change from Baseline </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="1">Difference= Median of [Vascepa % Change &#150; Placebo % Change] (Hodges-Lehmann Estimate) </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1">p-values from Wilcoxon rank-sum test </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1">*p-value
&lt; 0.001 (primary efficacy endpoint) </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1">**p-value &lt; 0.05 (key secondary efficacy endpoints determined to be statistically significant
according to the pre-specified multiple comparison procedure) </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1">Apo B = apolipoprotein B; HDL-C = high-density lipoprotein cholesterol; LDL-C =
low-density lipoprotein cholesterol; non-HDL-C = non-high-density lipoprotein cholesterol; TC = total cholesterol; TG = triglyceride; VLDL-C = very-low-density lipoprotein cholesterol </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="1">Note: All endpoints in the above table for MARINE were statistically significant with the exception of HDL-C. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Amarin has made significant progress in its efforts to expand the patent protection for Vascepa in the United States to at least 2030 with seven patent applications either issued, allowed or in progressed
states of prosecution and over 25 additional U.S. applications pending.&nbsp;Amarin is awaiting a decision from FDA as to whether Vascepa will be granted five-year new chemical entity (NCE) or three-year new product marketing exclusivity under the
provisions of the Hatch-Waxman amendments to the Federal Food, Drug, and Cosmetic Act. Typically, FDA&#146;s determination on the exclusivity of approved products is made public through the posting on FDA&#146;s website in the Orange Book. This
typically occurs mid-month following the month of an NDA approval. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Vascepa<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (icosapent ethyl) capsules </FONT></B></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vascepa<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> (icosapent ethyl) capsules, known in scientific literature as AMR101, is a patented, ultra-pure omega-3 fatty acid product, comprising not less than 96% EPA in a 1
gram capsule. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:18px;margin-bottom:0px">


<IMG SRC="g386563g54o42.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>IMPORTANT PRESCRIBING INFORMATION </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Vascepa&#153; (icosapent ethyl) is indicated for use in the United States as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe
(<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>500 mg/dL) hypertriglyceridemia. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The effect of Vascepa on the risk for pancreatitis in
patients with severe hypertriglyceridemia has not been determined. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The effect of Vascepa on cardiovascular mortality and morbidity in patients
with severe hypertriglyceridemia levels has not been determined. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The daily dose of Vascepa is 4 grams administered orally. Patients should
engage in appropriate nutritional intake and physical activity before receiving Vascepa, which should continue during treatment. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">FULL VASCEPA
PRESCRIBING INFORMATION CAN BE FOUND AT <U>WWW.VASCEPA.COM</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>IMPORTANT SAFETY INFORMATION </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attempts should be made to control any medical problems such as diabetes mellitus, hypothyroidism and alcohol intake that may contribute to the lipid
abnormalities. Lipid levels should be consistently abnormal before initiating Vascepa. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Medications affecting coagulation (e.g., anti-platelet
agents) should be monitored periodically. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In patients with hepatic impairment, alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) levels should be monitored periodically during therapy. Use with caution in patients with known hypersensitivity to fish and/or shellfish. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The most commonly reported adverse reaction (incidence &gt;2% and greater than placebo) in Vascepa treated
patients was arthralgia (joint pain) (2.3% for Vascepa vs. 1.0% for placebo). </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Severe (<U>&gt;</U>500 mg/dL) Hypertriglyceridemia
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Severe hypertriglyceridemia refers to a condition in which patients have very high levels of triglycerides (<U>&gt;</U>500 mg/dL)&nbsp;in
the bloodstream.&nbsp;Amarin estimates that approximately 4&nbsp;million people in the United States have severe hypertriglyceridemia.&nbsp;According to <I>The American Heart Association Scientific Statement on Triglycerides and Cardiovascular
Disease</I> (2011), triglycerides provide important information as a marker associated with the risk for heart disease and stroke, especially when an individual also has low high-density lipoprotein cholesterol, or HDL-C (often referred to as
&#147;good&#148; cholesterol), and elevated levels of LDL-C (often referred to as &#147;bad&#148; cholesterol). The effect of Vascepa on cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Conference call for investors </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amarin will host a conference call and webcast for investors, today at 7:00 p.m. EDT to discuss FDA&#146;s approval of Vascepa. The conference call will
be webcast live and a link to the webcast may be accessed from the &#147;Events&nbsp;&amp; Presentations&#148; page on the Amarin corporate website at <U>www.amarincorp.com</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">To listen to the live call on the telephone, dial 1-877-407-8033 (United States and Canada) or 1-201-689-8033 (International). The conference call ID number is 397905. A replay of the call will be
available for 30 days by dialing 1-877-660-6853 (United States and Canada) or 1-201-612-7415 (International), account number 286, conference ID 397905. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>About Amarin </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amarin Corporation plc is a biopharmaceutical company
focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin&#146;s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> (icosapent ethyl) is Amarin&#146;s first FDA approved product. For more
information about Vascepa visit <U>www.vascepa.com</U>. Amarin plans to separately seek approval for the use of Vascepa in the treatment of patients with high triglyceride levels who are also on statin therapy for elevated LDL-C levels, the
population studied in Amarin&#146;s ANCHOR trial, after Amarin&#146;s REDUCE-IT cardiovascular outcomes trial is substantially underway. Like Amarin&#146;s MARINE study, each of Amarin&#146;s ANCHOR and REDUCE-IT studies is the subject of a Special
Protocol Assessment (SPA) agreement with the FDA. For more information about Amarin visit <U>www.amarincorp.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Forward-looking
statements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press release contains forward-looking statements, including statements about the efficacy, safety and therapeutic
benefits of Vascepa, clinical trial results, the clinical importance of certain biomarkers and the impact of Vascepa on such biomarkers, the timing of a commercial launch of Vascepa, the potential additional indications for which FDA marketing
approval of Vascepa may be sought and the </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
commercial potential of Vascepa, the potential for an acquisition of Amarin or a strategic collaboration with a third party for the commercialization of Vascepa, the timing and outcome of
FDA&#146;s review determination of whether Vascepa should be granted new chemical entity or new product marketing exclusivity, the status of patent applications currently under review by the United States Patent and Trademark Office, the coverage
and expected expiration dates of those patent applications and issued patents and the ability of Amarin to protect the commercial potential of Vascepa. In particular there can be no assurance that Vascepa will be awarded five-year new chemical
entity or three-year new product marketing exclusivity and the FDA may take longer than expected to reach any such determination. Amarin&#146;s patent portfolio directed to the formulation and uses of Vascepa is still evolving and some patent
applications may not issue prior to commercial launch, if ever. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially
from those described or projected herein include the following: uncertainties associated generally with the commercial success of new pharmaceutical products, such as Vascepa; Amarin&#146;s ability to negotiate and execute a successful acquisition
of Amarin or a strategic collaboration with a third party for the commercialization of Vascepa; Amarin&#146;s lack of experience with commercializing pharmaceutical products; risks associated with preparations associated with a commercial launch;
the risk that FDA may not grant new chemical entity or new product marketing exclusivity to Vascepa; the risk that FDA may not reach a determination with respect to these matters on the timetable that we expect; the risk that patent applications may
not result in issued patents, and that issued patents may not prevent competitors from competing with Vascepa; the risk that competitors may challenge the validity, enforceability or both the validity and enforceability of our patents or seek to
design products around our issued patent claims and gain marketing approval for generic versions of Vascepa or branded competitive products based on new clinical studies; and the risk that trade secrets may not be maintained and that circumstances
that create manufacturing barriers to entry may not last. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in the &#147;Risk Factors&#148; section of Amarin&#146;s
filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or
otherwise except as required by law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amarin&#146;s&nbsp;product candidates are in various stages of development and are not available for
sale or use outside of approved clinical trials, except as it relates to the FDA approval announced herein. This press release is intended for communication with investors. Nothing in this press release should be construed as marketing the use of
such product candidates. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Investor contact information: </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Stephen D. Schultz </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Director, Investor Relations and Corporate Communications </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amarin Corporation </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In U.S.: +1
(908)&nbsp;719-1315 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Direct: +1 (908)&nbsp;326-1323 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">investor.relations@amarincorp.com </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Gitanjali Jain Ogawa </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Trout Group </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In U.S.: +1 (646)&nbsp;378-2949 (office) </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">+1 (650)&nbsp;269-7523 (mobile) </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gogawa@troutgroup.com </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Media contact
information: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">David Schull or Martina Schwarzkopf, Ph.D. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Russo Partners </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In U.S.: +1 (212)&nbsp;845-4271 or +1 (212)&nbsp;845-4292 (office) </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">+1 (347)&nbsp;591-8785 (mobile) </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">david.schull@russopartnersllc.com </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">martina.schwarzkopf@russopartnersllc.com </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g386563g05u28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g386563g05u28.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"``V`+H#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V"[ED@LYI
MHH3/)'&S)$IY<@<`?6O-[GXO75E.8+OPS+;RKU22<J1^:UZ=7F?QDTKS+.QU
M9%YB8P2'V/(_4'\ZWHJ+ERR1E5YE&\6:&B>/];\0DG3?"C21@X:5KH*@/U*U
MW+-((2RH&D"Y"YP"?3->-_#KQ))I-G=QDEHK>5)W3UC;Y'(]P=A_.O4]5UVU
MTW3X[E")WN<+;1(>9F/3'MSUJ*[C";C:UC>A1J5(1DM>;3YK^KG)ZU\1M8\/
M2K'JGA5H=_W'%T&1OH0M;'A/Q5J/B221KC09M/MECW)/(Y(<YZ#('US7&#S/
M&_C=8[N82:7HZF2X?^!F'+8]B1@?[*UUEQ\4/"5J=@OVE`_YY0L1_*M90]U)
M1U^>ASWM)WEI^9U]%<[HWCOP[KMRMK9WV)W^['*A0M],]:W+N[M[&V>YNYT@
MAC&6=VP!6#BT[-&J::NB:BN,G^*_A2&8QBZGEP?O)"2/UK:T+Q7H_B0R+IER
M97B`9T9&4J#TZBFZ<TKM"4XMV3-FBJ6J:QIVBVWVC4KR*VC/0N>6^@ZFN7?X
ML^%$D*"XN6Q_$L!Q1&$I;('.*W9VM%8>A>,-$\1S/!IMT9)43>R-&RD#.,\C
MWJQJWB32=$.V^NU20C(C4;F_(5$O<^+0TIPE5=J:N_(U**YFU^(/AVZE$?VI
MXLG`:6,@?G6MJ6NZ9I$,4U]=+%',<1M@L&XSQBH4XM73-IX2O"2A*#N]M#0H
MK`7QQX<9'8:D@"#)RK`GZ<<U63XB>'7E">?,H)^^T)VT>TAW+6!Q3VIO[F=1
M145O<0W<"3V\JRQ.,JZ'((K,U/Q7HND3M;WEZ%F7&Z-5+$?D*IR25VS"%&I4
MER0BV^UC8HKFH/B#X<GD"?;'3/\`$\3`?G6\][:Q6ZW$ES$D+XVR,X"G/3FE
M&49;,JKAZM'^)%KU1/14*7=M(JLEQ$P=MBD.#ENN/K[5-5&(5C>+=*_MKPO?
MV(&7>(M'_OKR/U%;-%-.SN)JZL?.7A:X6#7X8I3MBNPUM)GL'&/T.#^%;<UW
M<Z7ICW,\DC7*;K.Q0G.QOXV`]@<?5AZ5D^,=,;1/%U];(-BB7S8B.RM\P_+.
M/PKKO!]M+XV\6C6;NW6.RTU5VQ#[IE//ZMEC^%==:E&<XUGLOZ16%QM2A0J8
M>.\OP[_>CJO#/A&72/`L^G)LCU"^A8RN_179<`'V`_K5KPKX*T_P_I$4%Q:V
MMS>8)FG,8;<<]`2,X'2L+XE>-[S1)HM(TI_*N9$\R68#)13P`/<XZTS3OAQ?
MZA9Q76M>)=2-S,H=HXY3A,]LD\U%I./-)VN<^E[15[''>,;>&S^)+Q:;&L&)
MX2JQC`5SM/'IS6[\9=1N#J%AI@9A;B(S%1T9B2!^6/UKF]/TZ-?B9!I\<LD\
M<.HA!)*<LP1NI/X5Z[XL\'Z?XMMD2X=H;F#/E3I@E<]B.XK:4E"4+]C*,7*,
MK$7A:R\,77A^V33;>RN(O*'F916;=CG=GG.?6H-#\-P>"IM=U5Y8_LDW[V.-
M%P8D7<=OZ\5YSK?@'Q%X21M3MK@2P0\F>U<HZ#U(Z_EFM6U\7ZAKGPWURVOG
M\VYM4C'G8P71F`Y]^/UJ'3;5XRNF6II:25FC-T2"Y^)'C@S:F[&V0&5XP>$C
M!X0>F21^M>P1Z!H\5L+9-*LQ"!C9Y*D?RKSKX+QH9M6E_C"QJ/I\U>JU&(DU
M/E6R*HI<MWU/-K'2I_!&I>)=9^RI#:N`EB`1AMS9``[`'%1>`]&CUW4KK5=3
M'VGRF&!)R'<\Y/KCT]ZW/B=(R^'X(QT>Y&?P4UA>$O!T&N:,;V2_N8&\UDV1
M$`<8KSJTY5*RNKV/J<#3IT,NE/FY7)VO:_R_,U_B/I=E'H<5Y%;QQ31S*@9%
M"Y4@\''TJIHEX9OAE?\`VA5D^RAXXRXS@$#&,^F:O-\,[)QA]5O6'HQ!IGB'
M28/#/@&YL;>5Y%FF7+/C))(]/I4.,E)S:MH53K4)4J>&C-R?.GLUI<QOAWHM
MCJD][+?6J7"PA`@<9`)S_A70^+O">E'0;FZM+.*VN+=/,5HEVY`Z@CZ5!\+X
M-NCWD^/]9/M_)1_C6WXRN5M?"E^Q."\?EK[ECBG"$?8ZHC%8FM_:?+"3W2M]
MQS'PNOY2][IS,3&JB5`?X3G!_I6];^$HY/$]]J^I+!<I*1Y$17=L]R#QGBN*
M\(:A_86G:KK)3>55((E/1G8D_P!,UI:%8:YXS26^OM:N;>V5]BK"=N3WP!P!
MS44Y)QC&UV=.-H2C7JUHS4(NR;ZWT>EOQ+/Q+LK*WTZSEAMHHI3*5#(@7*XZ
M<?A6GX-M9+WP59Q2O\@FW#(SE5?./TKC_&NAQZ%+:1+?W5T959CY[YVXP.*]
M$\)0_9_"NG(1@^2&_/G^M73NZS=K'/C.6&6TXJ7->6_WC+3P[]GU!;N2Y\P)
M*\RILP`[`ACU^GY5MT45U'SH4444`>7?%W0Y;B]TR_M8B\L[?92%'5NJ?UKN
MO"^@Q>'-`M].CP74;IG'\;GJ?Z?05IRP13F,RQJ_EN'3<,[6'0CWYJ2M)5&X
M*/8A02DY'C'Q8TR\M_%"ZIY+M;31(%D"Y567@@^GK^-;MC\5;S48H[73O#4]
MS>E0N%?Y,^O3@?6O2&574JZA@>H(R*2.*.(8CC5!Z*,5?M4XI25[$>S:DVGN
M>">'KYM*\<+JNKVMR!'-*THBB+$.<CCU&3706_C23P_XYU34;JQO'L+\C;E"
MI"C&U@#QTKUW`]*1T21=KJK#T(S5.NI/6(E2:6C/,O$?Q+M-;T>?2M#T^]GN
M+M#&2T6-H/7`&235WP=X"EMO"&HVNJ+Y-SJJ8*=3$H'RY]\G-=]'!%%S'$B?
M[J@5)4.K:/+%6*5.[O)W/"--N=?^&VO2-<6#-&XV2*0?+F7/!5AWKKX_C':3
M86+0KV24_P`",#_+_"O1F177:ZAAZ$9K(UK0'U*W"6.IW.E./X[4*-WUXS^1
M%6ZL)N\XZDJG**]UF->PZEXU\(2O/IC:=<K+OMX)6^9@!WZ8SDUR_AWQ->^$
M'FLKVPE:%FW&-OD9&Z9&>M6E^''BW3;E[C2O%'SN<L79U+_7J#5U+?XGV^%E
M.E7ZK_SUVY/Z"N>IAXRESPDD>KA,R]E1>'K4^:++T/Q#>^<1:=H%W<2'H-PQ
M^)`--^)=PX\/V<3C:\LP9ESTPIR/S-.AU/X@P*%?PSISC_IE=!?ZUS?C;4]9
MO?L<.L:4FG/'N=%2<2[\X&>.G2L*T)0IMRE?[CLR^I1K8VFJ5/EM=[M]#0\(
M^,=*T'1%LKN*Y\SS&<LD8*G/XU%KFKZCXYGBL-(L9EM$;<6<8!/JQZ`"MGP_
M<ZW;Z%9P)X56XB6(%)6O(UW@\YP1D=:V8M1UX``>&HXQZ?;DX_):%0FX)-Z?
M(*N84*6)G5A3O.[U;=O6UOU.?\0^%9-/\"Q6=DIGDMYA-.5'+G!!('MG\A6/
MX5\;+H.FG3Y-/DN#YA9#&<'GL17H"7>MOUTFV3ZWF?Y)3XX[[?YAL[&-CU(<
MD_\`H(H=!J5XNQG3S.,J+I8B'/=WWMJ>7^,+[4M8OH+F[TR6S4PXBC())7)Y
M->D^&=4M-2TB(6BRJMLJQ,)(RIR%%:*"Y/\`K##_`,!!-3`8';\*(4W&3E>]
MR,3CH5Z$:2AR\NVO]?F+1116QY@4444`%%%%`!1110`4444`%%%%`!1110`4
M444`(PW*0"02,9':N/N?AS:WDOFW6K7\S_WI&#']1114RA&6YT4,35H-NE*U
MS4T/PPNASF2/4[RX39M$4KY0>X%;M%%-1459&=6K.K+FF[L****9F%%%%`!1
%110!_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g386563g54o42.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g386563g54o42.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"`#:`*8#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#QW-%%%`"T
M9I*6@`S1DT$8HH`7/%&:2EQ0`HHI*.]`"YQ29HQ1B@!:*0\T=J`#-&>:.U%`
M`324'I24`%+244`%%%%`!1110`444M`"4N**6@!,4N:*3O0`O>CO1BB@!:**
M*`$HS12T`--%+F@"@!*2G=J;0`4444`%%%%`!1110`I%%)2T`+BB@44`%%'>
MEH`****`"BBC%`!24N**`"BBB@!#3:=3:`%P/6DHHH`****`"BBB@!:`,T4H
MH`.E+24M`!3XHI)Y4AAC:21SM5%&2Q]!3*U_"9(\46!'42?T-`&S8?"WQ3>J
MK-;P6H/_`#WG`/Y#-;$'P3UJ0`RZKI\?L-[?TKT^R8E%^E:<1X%3<9Y2GP+O
MS][7[0?2!S_6I1\";C'_`",,'_@,W^->M*:>#0!Y`WP*O1]SQ!;'ZV[#^M5I
MO@=K"C]WK%@_L5=?Z5[3FHW/%,#P#4?A-XJL(VD2WM[M5&<6\P+?D<5QCJR.
M4=2K*<$$8(-?4\QXKYH\0C'B/4A_T]2?^A&A",VFTZDI@%)110`4444`%%%%
M`!2BDIW;F@`S2T@I:`"M/PW<1VOB"TGE8*B/DDG`'%9E200O/,D4:,[N0JJH
MR2:`/=K#QAHQ4`7.XC^XI-:T7BW2\<&4_P#`,?UKD/"?PQ>"V6;5I]KOAO)C
M.=OL37<VOAS2;-0([1"1W;DU!0U/%NGGI',?P'^-2#Q78_\`/"?\A_C5Q+:V
MC&$MXQ_P&I`L0&!"G_?-`BA_PE=A_P`\9OR'^-1/XMTT?>$H_P"`?_7K2,4)
MZPI^502Z3IUT"LMJAS[4`8UUXST6,?/<^7G^^A%>"^()8[CQ!?S1,&CDN'92
M#D$$UZ[XT^&1O[0W&C2XECRWV=SQ)[`]C7BT\3P2M%*C(Z$JRL,$$=JI`R.F
MTZFFF(2BBB@`HHHH`****`%I0:;2T`.HI**`%'6NY^&&GQ3:R]_,H/V<8C![
M,>_Y5PPZUV/A+55T33GNW1Y`\VP(AQVI-V14(N<E%;GNT#@H,5+7/Z?K&^-2
M(3R.[5JI?@J6*``#))-%F(MT8K.A\0:=,2([NW<@$G:^>`,D_E3QX@TT]+RW
M/&>&HLP+V*4=:HG7+`2"/[5;[SC"[O7&/YBFIK$%P\B6\L4K1<.%.=O^<4<K
M`TGD`6O$/BSI,5MK<6HP*%%V")`/[X[_`(C^5>J76JRH#^Z4_B:\Z^*#?:=%
MM+D_*?.Z=>H/^%.S`\PII.:=3:!"4444`%%%%`!1110`4HHI0*`#K1FBEH`*
MW[/_`)%L?]?7]*P*Z"R_Y%H^UT/Y&HG\+.G"_P`>/J>LZ;/;H(H6GB65E&$+
M@,?PK9L[JSN97@BN899$'SQHX)7MR.U<1?/!I>M:'K,P5(RK6\SD=`4RO\C4
ML^K76C6MW?PWL$=[*$N)+86OF-N8_*CM_"`FT#WS75&',M#EE*S.Z@T?3H3F
M*QMT)SG;&!U&#^E3)I.GI]VQMQ](Q7+7'B&]37I;*ZOSI(#QBU62UW17"D`M
MESW/(`XJ[IMWK>OZ0^KV^HK9([L;>W\E2OEJV/G)!))`/2E[-I78N9&^UC:&
M0R&UAWGJWEC-0"RMK<NT%O'$7Y8HH&?K^=<K:^(]<U**WU&U%TRSW87[*MGF
M)8-V"WF8^]WSG%01:WK4>D66MSZH)89=0^SO;M`BJT9<KG<.<\9JO9-"YT;]
M\GRGBN#^(_\`R+5M_P!=A_6MF#5;Z^U5[>#4/M,+VYG#O;>6H^?`"'`++CO[
M5C?$?_D7+?\`Z[C^M9R5BD[GF--IW:FFLQB4444`%%%%`!12TE`"TO7O24`T
M`+^-+24M``.M=#9_\BTW_7T/Y&N>'6NALS_Q3+_]?0_D:F?PLZ,+_'CZGJ@T
MBWUG3;6"Y&Y$>.;&.I7G'X]*GN?"'VZ2^_XFMQ#;W\J32P+&A&]<8Y/..!Q6
M5?2W9LK&VM%=GDA+[4S\Q&U0..PWD_\``:?'J7B=E@,*7F6`<J;(`*05W)SU
M4+NQG!)Z$ULI-;'/))MG0MX9-ULBOM4GNK1+C[0+=XU`WYR!NZ[<]JFT[PT=
M+'DV>K7<=CO+BT(0J,G)4,1G%<I<:SXMM;%)F2]C,2LTDCPKLDR&"X&T$?,%
MP#@C<.M61/XW9V2-KP(`3"TENNYPQ8`OQ@$?*<=:.=["Y4;L&A?\(_92FTU.
M_-E$'>.R"JX!.3M!"[B,GI6/X=\,"]\-:>NJ37;+`K'[')'Y:Q2'.3T!8C<<
M9]:EMD\2PIJ=[)]MDNTM1':B1`0<RN=P`'+*NVLV6U\3?;Q=S7%\C1!"9I%4
M1A<`$D'C@2/G_=I^T=A<J-.V\.)I$HF&H7-R4MQ;*)@N%13E0,`=*Y/XC<^'
M(/\`KN/ZUKZ=)JU]J-G=WYEW/;AP",#9M;/`]2R?KZ5D?$?CP]#C_GL/ZU+=
M]RK6/,<4TTXDXIM0`E%%%`!12YHH`2BBB@`I<44H%`!2T44`*.M;]F?^*:D_
MZ^5_D:P%ZUO6G_(N2?\`7RO\JF?PLZ,-_&CZGLNC*&L[9MH)$2X..1P*T=3N
MIK'1;VZ@4M+#`[H`,Y8#CBL_0^=/MC_TR7^0K?A'2M#&7Q,X2;Q3=Z3"%L[J
M?4(\-+(]]"3G"G[C?W=R$CCJP]JF;QGKJ9^6"155V#I:/AAG"L03POH1G/?%
M=O.UG*R65T\3--RD+D$OMYZ=\8S5P$_WOUH)/.SXIU]]3\R*,+'*=J"2%]FU
M6+<`#.XHRY/^R:Z7P]?7FJ:,+F_5?,=V&!'M4J../4=<'C([5NEN^\<_[76H
MY!GK0!DWJC:3@9Q7G'Q'_P"1?C_Z[C^M>E7P^4UYM\2!C08QZ3#^M/H!Y?3:
M=33Q4`)12TE`!1110`M%+Q24`%+THI:`$I:**`%4<UNVA_XIR4?]/"_RK#4U
MMVA_XIZ;_KNO\JF7PLWP_P#%CZGM.@C.FVO_`%Q3^0K?B'`K"\/\Z5:?]<4_
MD*Z"$<5HMC*7Q,H7>G2OK2:J@3_1K*6./:N9#(Q!_$87UZFN4TGP=JTUH]S/
M##'*R[8XKAG&6_=JTA!'!(5SR.K=*[6[U+[')L\@R'C^+'^>WYTDNN6\$IB:
M&5F&>%`[?Y-!)R,7P[NRD0N;BV<I@9!8X7Y,@<?]=,?5:[J052CUR*:=(DMI
M_G(`8K@#-7W%`&9>+\IKS/XDC_B1K_UV7^M>GW@^4UYG\2Q_Q)1_UU6GT`\K
MIIIU)4`)12FDXH`**7`HH`,4N,448-`!2@4H%21PO*VU!D_RI`18HQ5H6A)Q
MYD>?8YIXT]SR)$_6BX[%,5LV?_(O3_\`7=:SWL+A(S+LW(O5E.<5M^%([6Z\
MRUO#F-F!V[L<TGJBZ4N2:DSTW2M;%E8VT;V=PZ+;1GS$3(8[1D#Z<5MP^*+4
MR^6MI>,P](NO7/Y8JKI)BBMHXHI2$10JC=G`%;D,O`_>&K4D3+5ME^"198DD
M4'#J&&>O-2Y&<X'%5%E/]^G><?[]',A6+)?WJEJ-VUI83W"1&5HHRP0=6QVH
M:8_WS5>6;@Y<_G1S(#)EUQ[B>&--/G,4JJ?/_@&X9_&N)^))SHI_ZZK7=W4J
M!<;R`/\`:Q7F7Q$N86M4B20%C(#C.:.8+'GYZTE+24A!28I:*`$Q12T4`+2B
MCBEH`45>TXQN\EO),L*S+C>W0$<C/M5(4N:35QIV.TTCP=/-"9%FTFY7/#&^
M5?T-:4WA2YAB+>5HP7.3F_3@<>G^>:X!)0!S_*I1,I'('Y5-F/0U+S3H]++S
M-J5I))@[8;:0R$YXY.,8Q7.K--;2;H\C'I5N216J'(S32"YIV7C#4;/`#/@5
MMVWQ+NX\!P3^%<LNWVJ10O\`=%%@N=LGQ3('S`_A3_\`A:JX^ZU<2%3^Z*7"
M>@_*@#L'^*>>B-^54Y_B;<N#LC;\JYKY/0?E2?)Z4PN7[SQQJET"%W+FL*:Z
MN;N0R7!9C[U;.VH7VT"*V/:DJ5L8IAIB&T4M%`"44N**`&YH!IF:,T`2!J7=
M4>ZC)H`DW&E$E19I=U("0O2AJBW4H:@995Z>)*K*]/#T`6`]+O)%5]]'F4`3
M[Z"]0[Z3?F@"0O[U$S4A:F,U`"EJ9FD+4F:8AV:,TS=[T9H`?FBF9HH`;13:
M*`'49H'2D-`"T9-)0*`'9I0:;10`_=3M]14M`$NZC?47>EH`DWTF_P!Z910,
;<6I":;0:!!FDS10.E`!12&DH`=FBFT4`?__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g386563g60u40.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g386563g60u40.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"``Z`28#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V2BBB@`H)
M`&2<`45!>W<%A8SW=RP6&",NY/H!S0!Y=\0OBB@271O#LVYCE)[Q3P/54_Q_
M*M/X0>*#JFBOHUU)NN;#F,L>6B/3\CQ^5>/:O')+<MJ8LC:VE_)));@#"[=W
M('TJ;PQKLWAOQ!:ZI%DB)L2*/XT/WA^5=SI+DLCE51\UV?4%%16MU#>VD-U;
MN'AF0.C#N",BI:X3J"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BN+.M^(QD?V[X1!'K*_P#\
M53&UKQ-CY?$'A'_OM_\`XJKY&3S';UYY\4=2GO7T_P`'Z<V;K4Y%,V/X8\]_
MY_05--KGBB*)Y6\1^$@J*6.&8G`_X%7(>%+G5M:\077BR35]$MKLDQ(M\Q`Q
M@#*KD$#''XFM(0M[SZ$2E?0[?QEX(M[_`,")IEC$//TR,-:XZL0/F'_`AG\:
M^?R"#@C!':OH>WU+Q)<2I''KOA>1F.`L8=B?I\]>6_%+PN=!\2-=P)ML]0S(
MF!PK_P`2_GS^-:T96?*R*BZH[#X->)_M5A+X>N7_`'ML/,MLGK&3ROX'^=>H
M5\LZ'J]QH.LVNIVI_>6[AL?WAW'XC-?3NFZA;ZKIMO?VK[X;B,.A]CVK*O#E
ME==2Z4KJQ9KSOQII/BC1]*OM:L?&%V4A)D-L\:@*I/12/3->B5SGQ!&[P'JX
MQG_1S_,5G!VDBY;'A_\`PL'Q?_T'KK]/\*]8^%?BV?Q%HTUKJ%P9K^T?YG;J
MZ'H?PY'Y5YOXA\.8\!:!XAMTZQ>1<X'^T=K?T_*LWP/XA;PUXIM;YF(MW/E7
M`]4/4_AP?PKKE",X.R.>,G&6I]*TA(`))P!R2:%970.A#*PR".XKD?B3KDNF
M>'AI]D2=0U5_LT"KUP>&/Y''XUQ15W8Z6[*YYEXI^).NW/B*[?2=4FMK%7V0
MK'C#!>-W3N>:=X3\0^,/%'B&#2E\37-OYH9FD(#8`&3@8ZU4^(VBP^';O2-*
MB`_<6"^8P_B<LQ8_G4GPD_Y*!:?]<I?_`$$UW6C[.Z1S7?-9GM^AZ9>:59M!
M>ZO/JDC/N$TRA2!CIQVK2HJO?WL&FV$][<N$AMXS(['T`KAW9U;'F_Q#^)RV
M(GT70I";L$I/=#@1>H7U;W[5T?PY\5_\)/X<4W$FZ^M,1W&>K>C?B/US7C/B
M2TU74XF\87,`2UU*Y=4P/NXZ9]N,9]C2^!?$S^%O$L-VS'[++^ZN5]4/?\.M
M=;I)PTW.=3?-J?25,F1I8)(TD,;.I4.O521U%*CI+&LD;!D8`JPZ$'O3JXSH
M/*/'<OBWP98VMW#XMN+N.:0QE9+=%93C.<XYZ5PZ?$#Q?<3)&=>N5WL%RH48
MR?I7HGQO_P"1<T__`*^__9#7C5G_`,?UO_UU7^8KNI).%VCFFVI61[K/X)\5
MB/=:^/;XR8R!-$-OZ&N,U+QGX_\`!.JBRU:XBNAC<AEC#)*OJ&&#7MPZ#Z5Y
MA\<1;_V-IA;'VC[0VSUV[>?UQ6%.7-*S1I-65T;O@OXCZ=XL86DD?V/40,^2
MS963U*GO].M=-JUE<:AITEM:ZA+I\KXVW$0!9<'T-?-'AQYX_$NF/;%A,+J/
M9MZ_>%?4=*K!0EH.G)R6IXAXXU/Q?X.UB*R7Q5=74<T7F(Y55(Y(P1CVK-\/
M^*/&?B'7;72H?$=Q$]RV-[8(4`$D]/05J_&[_D9K#_KT_P#9C6!\,AGX@Z7[
M,_\`Z`U=$4O9WL8MOGL>L-X,\2^6-GCW4-^.<VZ8KR[7/%?C/0M:N]+F\17$
MCVLFPNF,'T/3WKZ$KR72]/M=5^,?B*QO85FMYH75T8=?N?K6-.6]S6:VL<KH
MOQ0\2Z=J<5Q>7\M_;`XE@EQ\R]\''!KW;1]8LM>TR+4=/F$L$HX/=3W!'8BO
M`/'/@B[\(:CQNFT^9CY$^/\`QUO<?K3/!7C.\\(:GYB;I;*8@7%OGJ/[P]&%
M:3IQG'FB9QFXNTCZ*O(9;BSFAAN&MI)$*K,@!*'U`/%>7^.+?QMX4TY=2M_%
M=Q>6H8)+NB1&0GH>!R*],TS4[/6-/AO["99K>9<JP_D?0UR_Q9_Y)]>_[\?_
M`*$*YZ;M)(VDKJYF^&=`\7:SHEOJ6H^,;ZU>Y4.D,4:':AZ$DCJ:*['PT-OA
M?2@>UG%_Z"**'-W&HJQR3Z!=EBW_``KC0V).?^/I,_\`H%1-X>NNWPTT0_\`
M;VG_`,35233-(#D?\(%XC.">5G;GW_UE59[#0X(GEF\$>)XHXP6=S.X"@=23
MOK3^OZU,_P"OZT,?QA:2+);:#'X+TO3=1OW7RGMY5D?&?8#;GU^M=-IWAG5;
M&Q@M7\`:'<&)`IEDNE9G/<DE>M<7X=TVWUC6+S5/^$:U;4=,#%+>*"8DQGMN
M<G)P/?O75KH^E`<_#WQ#D?\`3RQ_]GJY:*W]?F):ZG4:#HLD>I))=^#-(TY8
MP66XMY$=U;M@;1^>:N>./#:>*/#-Q9!1]I0>;;L>SCH/QZ?C3?!VFV-K:S7-
MKHU[I3RML>*\D+,P'0C+'CFNCKG<FI71JE='R6Z/'(T<BE70E64]01U%>M?!
MCQ/Q-X;N9.F9K7)_[Z7^OYUB?%SPP=)\0?VM;QXM-0.6P.%E[C\>OYUQ&F:A
M<:3J=OJ%JVV:VD#H?IV_'I7:[5(',KPD?5E<]X^_Y$76/^O8UI:)JUOKNC6N
MIVIS'<(&Q_=/<?@<BLOXA.(_`>KD]X,?F17#%>\D=+^$SO">DPZW\)[/3+D#
M9<VK+G^Z=QP?P.#7@VH6,^FZA/8W*[9K>0QN/<5]$?#K_D0=(_ZX_P!37GWQ
MG\.?9M0@U^!,1W(\J?'9P.#^(_E732G:;B93C>*9UOPH\2?VUX8%E/)FZT[$
M;9/+)_"?Z?A530_^*S^(]WKK?/IVB_Z/9YZ-)W8?J?RKR+0-:U+1KN7^RV(F
MO(FMBH[[N!CWSTKZ'\(:`GAKPU:::`/,5=\S?WI#RW^'X5-6*@VUU'!\R2['
ME'QK_P"1NM?^O-?_`$)JSOA)_P`E`M/^N4O_`*":T?C7_P`C=:_]>:_^A-6?
M\)/^2@6G_7*7_P!!-:K^#\C-_P`0^@:\^^(UY/K.HZ=X*T]R);YQ)=,/X(AZ
M_D3^`KN=0OH-,T^XOKIPD-O&9'/L!7C_`(8\0ZS%K5_XG?PIJ&IS:B<0S1@A
M8X\_='!]`/PKFIQ?Q&\WT/3M3\,6.H>%'\/",);B$1Q<?<('RM^=?-=_93Z;
M?SV-TA2:!S&ZGU%>W?\`"Q]=_P"A"U3\S_\`$UYWX_DOM:U#^VY/#-]I0V!)
MWE4E6/0'.!@]JVH\T79F52S5T=_\(?%7]J:,VBW4F;JP'[HD\O%V_+I^5>BU
M\N>'M;N/#NNVNJ6Y.Z%_F7^^A^\OXBOIO3[^WU/3X+ZU</!<('1O8UG6ARRO
MW+IRNK'GWQN`_P"$9L#W%Y_[(U>,6A87D!1=["1<*3C)STKVCXW?\BQ8_P#7
MX/\`T!J\:TT9U2T![SI_Z$*WH_PS*I\9[3KOCWQ;H%D;F]\'I#%P/.^U>8BD
M],[17E.K:_?>+]92XUF_CA!^56*'RX5]@,FOI*_L;?4K":QNXQ)!.A1U/<&O
MFCQ1X?N/#.O7&F3Y(0YB?_GHAZ&HH.+Z:E5$UZ'L7@;X:Z7H+Q:O)=KJ5T5#
M0RJ,1H#W4=S[UWM>-_"3QJ;6X7PWJ$O[F4_Z(['[C?W/H>WO]:]DK&JI*7O&
ML&FM#Q/XW?\`(S6'_7I_[,:P?AA_R4'3/J__`*`U;WQN_P"1FL/^O3_V8U@_
M##_DH.F?5_\`T!JZ8_POD8/^(?15>7>&O^2XZ[_UR?\`]DKU&O+O#?\`R7'7
M?^N3_P#LE<U/:7H;SW1Z-JFEV>LZ=-I]_"LUO,,,I[>X]"/6OGGQIX,O/"&I
M^4^9;*4DV]QCAAZ'T85](U1UG1['7M,ET[4(1+!*.?53V(/8BBG4<'Y!.',C
MP/P)XXN?".H;9-TVFS-^_A'\/^VOO_.O3_B;?6VI?#*:\LYEF@F:)D=3P1NK
MR3QAX1OO".JFVG!DMI"3;W`'$@]#Z$=Q5*#7[^WT"ZT02;[*Y97,;?P,#G*^
MF>]=3@I-3B8*3BG%GTEX>!'AO3`>HM(O_0113M!X\/:;_P!>L7_H(HKA>YU+
M8?JFKZ?HEI]KU.[CM8-P7?(<`D]OK7D?Q$^)]OK-F^C:&[?9I#B>Y(V^8/[J
MCKCU->O:C9VM];>5=VT-Q'N!V2H'&?7!K/C\.Z'@_P#$FL/_``%3_"M:=EJT
M9SOL<?\`#?QIX7L/"5KIUQJ$-C<P[O-68[0Y))W`]#QBO1X9HYX4FAD62.10
MR.IR&!Z$5E_\(]H>?^0-8?\`@,G^%:L<:11K'&BHBC"JHP`/0"IJ)7N.#TL.
MID\\5M`\\\BQQ1J6=W.`H'4DT^FRQI-&T<J*Z.,,K#((]"*S+/-?B5XQ\+:C
MX2N-/M]1@O;J1E,*P'=M8'J3T'&?SKQ7</45]2CP]HF/^0/8?^`R?X4O_"/Z
M)_T![#_P&3_"NN$U!62.>4>9W/&?AI\0K?PQYNF:JS_8)GWI(OS>2W?CT/M7
M4?$?QYX?O_!\]AINI17=Q=E0%BS\J@@DGTZ5WW_"/Z)_T![#_P`!D_PH_P"$
M?T3_`*`]A_X#)_A4OE<N:Q2NE8XKX<^./#\?A2RTV[U&&SNK8&-DG?;NYX(/
M?K78>)-%A\1^'KO3),?OX_W;?W7'*G\ZD_X1_10<C1[#(_Z=D_PK1`P,"LIZ
M.Z+CM9GAOPJ\*2W?BV:[OH2L>D,0RL.LW0#\.3^5>U7VH6>F6S75]=16T"D`
MR2L%4$].33H+>&!I6BA2,RN6<HH&YL=3ZFF7]K;WEHT-U;Q3Q$@E)4#*?P-$
MY.<M0BN6.AX/\5=:TW6_%:3:;=QW,45LL;2(<KNR3P>_6J7PXU:QT7QI:WFH
M7"P6X1T,C=%)4@9KW#_A'-#_`.@+I_\`X"I_A1_PCNA_]`73_P#P%3_"NCF7
M+RV,K>]<\V^(_P`1;#6_*T73)FDT_P`Q6NYUX\T`_=7V[_E7IOA_Q%X=U*WA
MM-%U"VD$<0V6Z-AT4#^[U&*9_P`([H?_`$!=/_\``5/\*LZ?I&F65SYUIIUI
M;R;2-\4"HV/3(%922Y;(N+=S4K#\1ZQX;AM+C3-<U*TA6>(AX99`&*GOCK]*
MW*IW6DZ;>R^;=:?:SR8QOEA5CCZD5E%79I+8^6)_)2XD6&3?$KD(QXW#/!KT
MOX5^/K/2()-$UFZ$%L6WVTSGY4)ZJ3V!ZC\:]7_X1_1/^@/8?^`R?X4O_"/Z
M)_T![#_P&3_"NJ<U)6:,(QY7='F7Q>\3:)JNBV5GIVI6]W,MSYC"%PP5=I')
M'UKRVPGC@U"VFD/R1S(S?0$$U]/?\(]HG_0'L/\`P&3_``I?^$?T3_H#V'_@
M,G^%*$U&-K!*-W<9I7B71-;;9IFIVUT^S>8XY`6`]2.HKG/B?X1_X2/03=VL
M>;^Q!>/`YD3^)?ZBNKM=+TZQD,EI86UNY&"T4*H2/3(%6ZY[\DKHV^):GR6D
MC1R*Z.4="""#@@BO=O!OQ/TC4M'BCUK4(;/4(1MD\YMJRX_B!Z<]Q712>'M$
M:1V;1[`DL22;9.?TIO\`PCFA?]`73_\`P%3_``KHG)36J,8IQ>AY#\6=<TS6
M_$5M)IEY'=1PVVQWC.5W;B<9[UC>`]6L]%\9:??7THCMT9@[GG:"I&?UKW[_
M`(1[0_\`H#6'_@,G^%'_``CVB?\`0&L/_`9/\*:FE'EL*UY7*DOQ`\)0Q&1M
M?LV&,X1]Q/X"O+O#/C72XOBA?:Y>N;>TOMZ([<[,XVEO^^?UKUL>'=#_`.@-
M8?\`@*G^%+_PCVB?]`:P_P#`9/\`"LXJ*3+;;+6F:QINLPM-IE]!=HAPS0N&
M"GT/I5VJ]I8V=BC+9VD%LK'+"&,("??%6*P>C-5J9VNZ%8>(M+ET[4(@\3CA
MA]Y&[,#V-?.OBSPK?^$]5:SNU+Q-DP3@?+*O^/J*^FZXGXMQ12>`[EWC1FCD
M0HQ4$J<XX]*UHS<78BI%-7.HT3_D`Z?_`->L?_H(HIVC_P#(%L?^O:/_`-!%
'%9/<M;'_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
